Exagen (NASDAQ:XGN) Announces Quarterly Earnings Results, Hits Expectations

Exagen (NASDAQ:XGN - Get Free Report) announced its quarterly earnings results on Monday. The company reported ($0.20) EPS for the quarter, meeting the consensus estimate of ($0.20), RTT News reports. The business had revenue of $15.50 million during the quarter, compared to analysts' expectations of $14.55 million. Exagen had a negative return on equity of 92.58% and a negative net margin of 30.36%. During the same quarter in the previous year, the business posted ($0.19) EPS.

Exagen Trading Down 7.3 %

Shares of NASDAQ XGN traded down $0.45 during midday trading on Friday, reaching $5.71. 357,579 shares of the stock were exchanged, compared to its average volume of 108,589. The company has a market capitalization of $102.79 million, a price-to-earnings ratio of -6.07 and a beta of 1.50. Exagen has a 12 month low of $1.38 and a 12 month high of $7.20. The company has a debt-to-equity ratio of 1.54, a current ratio of 4.05 and a quick ratio of 4.05. The business has a 50-day simple moving average of $4.54 and a two-hundred day simple moving average of $4.11.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on XGN. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $8.00 price target on shares of Exagen in a research report on Monday, January 13th. BTIG Research reissued a "buy" rating on shares of Exagen in a report on Wednesday. Finally, William Blair reiterated an "outperform" rating on shares of Exagen in a research note on Wednesday, March 12th.

About Exagen

Exagen Inc develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).